No Data
Express News | Dizhi Pharmaceuticals: Savolitinib has submitted a listing application to the FDA in the USA.
Dizhi Pharmaceuticals-U (688192): Domestic sales volume of Shuwo Tinib exceeded expectations, focusing on overseas declaration progress
1-3Q24 performance exceeded our expectations. The company announced 1-3Q24 performance: revenue of 0.338 billion yuan, a year-on-year growth of 743.97%; net loss attributable to mother of 0.6 billion yuan, corresponding to a loss of 1.35 yuan per share. The first three quarters.
Dizhi Pharmaceuticals (688016): Persist in research and development investment, the commercialization of innovative drugs is about to surge.
Event: On October 31, 2024, Dezh Pharmaceutical released the third quarter report for 2024, with the company achieving revenue of 0.338 billion yuan in the first three quarters of 2024 (+743.97% year-on-year), attributable to the listed company's shares.
Dizhil Medical (688192): Revenue meets expectations, research and development pipeline progressing rapidly.
The company released its Q3 report for 2024: In the first three quarters of 2024, the company achieved revenue of 0.339 billion yuan (+743.97%) and net income attributable to the parent company of -0.559 billion yuan (+32.63%), non-recurring net income
Express News | The social security fund held positions with a market cap of nearly 190 billion yuan at the end of the third quarter.
Digel Pharmaceuticals: Digel Pharmaceuticals: Report for the Third Quarter of 2024
No Data
No Data